0
Editorials: Point and Counterpoint |

Rebuttal From Dr O’Byrne

Paul M. O'Byrne, MBBCh, FCCP
Author and Funding Information

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: P. M. O. has held grants-in aid from GSK for the investigation of mepolizumab and from Medimmune for the investigation of benralizumab. He also reports consulting fees from AstraZeneca, Chiesi, Boehringer Ingelheim, GSK, Medimmune, Merck, Takeda, and Abbott and grants-in-aid from AstraZeneca, Amgen, Genentech, Novartis Axican, and Alakos.

Firestone Institute of Respiratory Health and the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada

CORRESPONDENCE TO: Paul M. O’Byrne, MBBCh, FCCP, Room 3W10, McMaster University Medical Center, 1280 Main St W, Hamilton, ON, L8S 4K1, Canada


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2017;151(1):20-21. doi:10.1016/j.chest.2016.09.024
Text Size: A A A
Published online

Extract

Dr Barnes makes a number of cogent arguments as to why new anti-eosinophilic drugs, which are biologic agents, will not be widely used in the management of uncontrolled asthma. These include the fact that most uncontrolled asthma is caused by lack of adherence to effective therapies (particularly inhaled corticosteroids) and that some patients with severe refractory asthma do not have persistent airway eosinophilia. He is also correct that the use of anti-eosinophilic biologic agents must be restricted to those patients with evidence of persistent eosinophilic asthma who are not responding to high doses of conventional antiasthma treatment, many of whom require oral corticosteroids to manage their disease. However, identifying these patient phenotypes that may potentially respond to a very specific biological treatment, even if they represent a small proportion of the entire patient population with the disease, is the whole purpose of precision medicine.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543